Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of Applied Physiology in which Dr. Marina García-de-Acilu and colleagues at the Vall d’Hebron University Hospital in Barcelona evaluated the utility of Masimo PVi® as a noninvasive method of predicting preload responsiveness in patients treated with nasal high-flow (NHF) therapy. They found that PVi may identify preload responders and noted that PVi may therefore be used in the “day-to-day clinical decision-making process in critically ill patients treated with NHF, helping to provide adequate resuscitation volume.”1 More than 100 independent studies have demonstrated the utility of PVi as an indicator of fluid responsiveness.2 This is the first time PVi has been evaluated in patients treated with NHF therapy.
Goldman Sachs, Neogrid, Zarpo e mais: confira vagas de emprego e cursos em TI
canaltech.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from canaltech.com.br Daily Mail and Mail on Sunday newspapers.
Masimo to Report First Quarter 2021 Financial Results after Market Close on Tuesday, April 27
digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.